Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480)
Health Care · Biotechnology · CN
HK$13.10
-3.68% today · -48.6% 1Y
Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480) operates in the Biotechnology industry within the Health Care sector. The company is valued at $332.05M and employs 193 people.
Over the last twelve months the share price has lost 48.6%, trading between 12.00 and 28.00.
Tweenvest scores Beijing Luzhu Biotechnology Co., Ltd. across four factors: quality 33/100. Its strongest factor is quality.
2480 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $332.05M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.75
- Dividend yield
- —
- Beta (5Y)
- -0.64
- 52-week high
- HK$28.00
- 52-week low
- HK$12.00
- Avg volume (3M)
- —
- Shares outstanding
- 198.91M
- Employees
- 193
- Next earnings
- —
About Beijing Luzhu Biotechnology Co., Ltd.
Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.
- ISIN
- CNE100005YD8
- Founded
- 2001
- Listed since
- May 8, 2023
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.